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Abstract 
BACKGROUND: Ischemic heart disease remains the leading cause of mortality and morbidity 
worldwide despite improved possibilities in medical care. Alongside interventional therapies, such 
as coronary artery bypass grafting, adjuvant tissue-engineered and cell-based treatments can 
provide regenerative improvement. Unfortunately, most of these advanced approaches require 
multiple lengthy and costly preparation stages without delivering significant clinical benefits. 
METHODS: We evaluated the effect of epicardially delivered minute pieces of atrial appendage 
tissue material, defined as atrial appendage micrografts (AAMs), in mouse myocardial infarction 
model. An extracellular matrix patch was used to cover and fix the AAMs onto the surface of the 
infarcted heart.  
RESULTS: The matrix-covered AAMs salvaged the heart from infarction-induced loss of 
functional myocardium and attenuated scarring. Site-selective proteomics of injured ischemic and 
uninjured distal myocardium from AAMs-treated and untreated tissue sections revealed an 
increased expression of several cardiac regeneration-associated proteins (i.e. periostin, 
transglutaminases and glutathione peroxidases) as well as activation of pathways responsible for 
angio- and cardiogenesis in relation to AAMs therapy.  
CONCLUSIONS: Epicardial delivery of AAMs encased in an extracellular matrix patch scaffold 
salvages functional cardiac tissue from ischemic injury and restricts fibrosis after myocardial 
infarction. Our results support the use of AAMs as tissue-based therapy adjuvants for salvaging the 
ischemic myocardium. 
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Introduction 
Ischemic heart disease has persistently maintained its rank as the global leading cause of 
mortality.
1
 Replacement of functional myocardium with a non-contractile fibrotic scar after 
irreversible ischemic injury over-activates compensatory mechanisms, contributes to myocardial 
rigidity and eventually to the development of heart failure (HF) over time.
2
 Therapeutic 
interventions alleviate symptoms, but fail to restore lost myocardial tissue.
3,4
 Regenerative tissue-
engineering and cell-based therapies have been suggested to directly or indirectly instigate recovery 
of tissue function. Many cell-based therapies have poor clinical translatability due to high 
complexity, costs, lengthy preparation times, requirements for special production facilities, and 
sometimes frank incompatibility with clinical practice.
5,6
 Although a plethora of cell types have 
been evaluated in clinical trials, none are used as a part of clinical practice.
7
 
Studies conducted with cardiac progenitor cells stimulated further interest in functional 
heart regeneration.
8,9  
Unfortunately, some studies were associated with major controversies and the 
cardiac cell therapy community entered a state of disbelief. The autologous cardiac origin and the 
claim for a rich cardiac progenitor pool in atrial tissue
10,11,12 
support its use for cardiac therapy.
13
 
The AADC consortium recently demonstrated clinical feasibility of intraoperative processing and 
epicardial transplantation of autologous atrial appendage micrografts (AAMs).
14,15
 
In this study we investigated the functional efficacy and molecular therapeutic mechanisms 
of epicardial AAMs patch transplantation in a murine model of myocardial infarction (MI) and HF 
(Figure 1). 
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Results 
Myocardial function 
Left ventricular ejection fraction (LVEF) and area under the curve (AUC) analyses 
spanning the 8-week follow-up period are presented in Figure 2A. Echocardiographic (ECHO) 
recordings demonstrated improved functional recovery in the AAMs patch group than in the ECM 
patch and MI groups. Lower initial LVEF values in the Sham group were due to lower weight of 
the group’s mice at the beginning of the experiment. 
In all intervention groups, LVEF decline was evident during the first two weeks of the 
follow-up. The acute declines in LVEF at one-week time-point postoperatively in AAMs patch, 
ECM patch and MI groups were 18.03 (54.49±2.93%-36.69±2.56%), 19.77 (52.15±3.10%-
32.38±2.96%) and 34.94 percent points (58.72±2.58%-23.78±3.16%), respectively, with a 
significant difference between AAMs patch and MI groups. In the later phase of the follow-up, the 
LVEF curves of the AAMs and ECM patch groups separated, suggesting prolonged therapeutic 
effect from the AAMs. Significantly higher mean LVEF values were observed in the AAMs group 
than in the MI group from 4th week onward until the 7th week of follow-up. The Supplementary 
Table S1 provides the values of all ECHO parameters. 
Figure 2A shows the LVEF measurements and AUC analysis over the entire follow-up 
period. Only the AAMs patch group demonstrated highly preserved LVEF function compared to 
MI group. The average LVEF AUC-values were 334.2±26.68 (AAMs patch), 277.1±19.85 (ECM 
patch), 213.4±28.55 (MI), and 354±8.21 (Sham). 
The functional state of the left ventricle was further assessed by strain analyses. AUC data 
is presented in Figure 2B-E and the complete strain analyses data is available as online 
supplements (Figure S1 and Table S1). Overall, strain parameters in both patch groups were well 
preserved, with the greatest preservation in the AAMs patch group. 
Mean circumferential strain values (Figure 2B) at the 8-week time-point were -13.5±2.48 
(AAMs patch), -12.2±2.87 (ECM patch), -7.0±2.04 (MI) and -15.1±2.57 (Sham). AUC analysis 
(Figure 2B) revealed preserved function only in the AAMs patch group. The average AUC-values 
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for circumferential strain were 78.6±15.04 (AAMs patch), 49.9±9.50 (ECM patch), 32.6±11.27 
(MI), and 89.46±12.30 (Sham). Mean circumferential strain rates at the end of the follow-up were -
4.2±0.65 (AAMs patch), -3.5±0.90 (ECM patch), -2.3±0.45 (MI) and -4.5±0.55 (Sham) and the 
corresponding AUC-values for the circumferential strain rate were as follows: 11.7±1.98 (AAMs 
patch), 7.9±1.27 (ECM patch), 5.9±1.56 (MI), and 13.31±1.88 (Sham). Again, the AAMs patch 
group demonstrated better recovery. 
Longitudinal strain showed no decline in either patch group, and only the MI group against 
the Sham group showed significant decrease (Figure 2D). Longitudinal strain values at the 8-week 
time-point were -13.4±2.16 (AAMs patch), -16.6±2.83 (ECM patch), -12.9±4.05 (MI) and -
14.4±2.41 (Sham) with the corresponding AUC-values being 81.8±22.23 (AAMs patch), 
69.1±10.87 (ECM patch), 56.1±15.65 (MI), and 109.4±12.67 (Sham) (Figure 2E). Longitudinal 
strain rate values at the 8-week time-point were -5.0±0.63 (AAMs patch), -5.2±0.86 (ECM patch), -
4.2±0.97 (MI), and -4.8±0.40 (Sham) with the corresponding AUC-values being 31.3±6.88 (AAMs 
patch), 21.2±2.67 (ECM patch), 17.2±6.00 (MI), and 33.8±5.12 (Sham). 
Atrial natriuretic peptide (ANP) expression 
ANP mRNA expression (Figure 2F) was significantly lesser in both patch groups (3.6±1.24 
for AAMs, and 2.3±0.41 for ECM) compared to expression in the MI group (7.9±1.70). The 
possible presence of ANP-expressing AAMs may raise ANP values in the AAMs patch group. 
Fibrosis 
Build-up of fibrous tissue was analyzed by the scar transmurality index (scar thickness 
divided by the wall thickness at measurement point, Figure 3A) and ventricular wall thickness 
(Figure 3B). The mean scar transmurality index values were 50.2±3.69% (AAMs patch), 
53.1±3.54% (ECM patch), and 81.3±4.26% (MI) with the least fibrosis in the AAMs patch group. 
The mean ventricular wall thicknesses were 0.21±0.01 cm (AAMs patch), 0.16±0.08 cm (ECM 
patch), 0,061±0.071 cm (MI), and 0.15±0.094 cm (Sham). The greater thickness in the AAMs 
patch group can be attributable to the transplanted micrografts. The AAMs group also had the 
lowest degree of scar dispersion by planimetry (Figure 3C), although both patch groups were 
significantly different from the MI group. The mean scar dispersions were 51.4±13.7° (AAMs 
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patch), 59.4±14.1° (ECM patch), and 152.4±9.0° (MI). Moreover, the spread of epicardial patch 
was 135.3±4.7° in the AAMs patch and 161.7±12.8° in the ECM patch group. Figure 3D shows 
representative histological images from each group. 
Endocardial interstitial fibrosis 
Overall, the degree of tissue fibrosis in endocardial myocardium was lower in both patch 
groups than in the MI group. The endocardial area is the least tolerant to hypoxia and is the first 
region to be damaged and scarred after an ischemic insult. Evaluation of the endocardial fibrosis, 
with collagen subtype characterization, is presented in Figure 4. In all analyses, both patch groups 
demonstrated significantly lesser fibrosis compared to the MI group. The mean content of collagen 
fibers was 3.23±0.83% (AAMs patch), 1.67±0.55% (ECM patch), and 15.2±1.96% (MI); bright 
fibers 0.035±0.013% (AAMs patch), 0.005±0.002% (ECM patch), and 0.309±0.088% (MI); green 
fibers 0.77±0.19% (AAMs patch), 0.28±0.062% (ECM patch), and 4.54±0.65% (MI); orange fibers 
2.43±0.65% (AAMs patch), 1.38±0.53% (ECM patch), and 10.32±1.32% (MI). 
Myocardium immunohistochemistry 
We evaluated the preservation of myocardial tissue with anti-cardiac troponin T (cTnT) 
immunohistochemistry (Figure 5A-B) and by quantifying the Picrosirius Red-negative area (Figure 
5C-D). The area of cTnT-positive tissue in the subtransplant area was larger in both patch groups 
than in the MI group. However, some MI-induced damage was observable across all interventional 
groups against Sham group. cTnT-positive tissue in the subtransplant encompassed 49.4±1.94% 
(AAMs patch), 53.6±2.46% (ECM patch), 35.0±2.28% (MI), and 99.68±3.52% (Sham). Within the 
site of infarction, significantly more Picrosirius Red-negative nodules were found in the AAMs 
patch group than in the ECM patch or MI groups (Figure 5C). Non-collagenous nodule amounts 
were 3.6±0.71 (AAMs patch), 0.7±0.28 (ECM patch) and 1.1±0.24 (MI). The nodules observed in 
the AAMs patch group were also significantly the largest as compared to other groups (Figure 5C). 
The mean Picrosirius Red-negative tissue area encompassed 1205±258 pixels (AAMs patch), 
141±49 pixels (ECM patch), and 258±75 pixels (MI) (see Figure 5D). These nodules remained 
cTnT negative (Figure 5B), suggesting that they do not represent contractile cardiac tissue. Figure 
5E presents representative histological sections from each study group stained against cTnT. 
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Proteomics 
In a separate experiment designed to compare AAMs and ECM patch molecular tissue-
level responses with the same MI model and the 8-week follow-up, label-free site-targeted 
proteomics was performed on samples from the following areas: (1) ECM or AAMs patch 
(transplant), (2) subtransplant and (3) distal septal myocardium (Figure 1). Our aim was to 
specifically dissect the therapeutic effect of AAMs from that of the ECM patch. All quantified and 
differentially expressed proteins (DEPs) are presented in Data File S1 and the proteomics data have 
been uploaded to the Mass Spectrometry Interactive Virtual Environment (MassIVE) for in-depth 
review (Supplemental data). The quantified proteins (1,005 in total) were assessed utilizing a 
Spearman correlation heatmap, which confirmed site-specific dissection of the transplant, 
subtransplant and remote septal samples. Samples from the patch transplant area clustered as a 
separate group, while the myocardial samples from the subtransplant and septal areas formed 
another major cluster. Within this myocardial cluster, samples from the AAMs patch-treated group 
from both subtransplant and septal areas clustered separately from ECM patch samples without 
micrograft therapy, suggesting a widespread independent therapeutic effect of AAMs (Figure S2). 
By comparing the AAMs patch group to the ECM patch controls, we identified 293 DEPs (45 
upregulated and 248 downregulated) in the transplant area. In the subtransplant area, 216 DEPs 
were characterized (151 upregulated and 65 downregulated), while in the septal area, 43 DEPs 
were identified (42 upregulated and 1 downregulated). All DEPs were scrutinized using Ingenuity® 
Pathway Analysis (IPA®) software to reveal associated canonical pathways, biological functions 
and disease states. 
Transplant/patch zone—DEPs associated with the pathways for Oxidative phosphorylation 
(activation), Actin cytoskeleton signaling (activation), Sirtuin and calcium signaling (inactivation) 
were altered in the transplant zone of micrograft-treated vs non-treated tissue (Figure 6A). In 
transplant, the diseases and functions feature revealed processes related to the survival of cells and 
tissues. Specifically, functional categories including Cell death and Necrosis were significantly 
downregulated (B-H z-scores -2.99 and -3.43, respectively; Figure 6B), while those related to Cell 
survival and Cell viability were upregulated (+3.09 and +3.36, respectively; Figure 6B). 
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Subtransplant zone—Pathways related to cytoskeletal changes and reorganization were 
activated in the AAMs patch-treated subtransplant zone: Regulation of actin-based motility by Rho, 
RhoA signaling and Actin cytoskeleton signaling (Figure 6A). From a metabolic perspective, 
Oxidative phosphorylation was significantly decreased, whereas Glutathione redox reactions I 
were significantly altered with increased expression of enzymes GPX3, GPX1, and GSTM2 in the 
AAMs patch-treated group (Figure 6A and Data File S1). Notably, functions related to muscle cell, 
especially cardiomyocyte, viability and new muscle formation (Formation of muscle [B-H z-score 
+2.80], Differentiation of muscle and muscle cells [+1.90], Apoptosis and cell death of muscle cells 
[-1.91, -1.92, respectively]) were significantly activated (Figure 6B). The inflammatory response 
(Inflammation of organ [-2.367]) and Oxidative stress (-2.236) showed decreased activity in the 
AAMs patch-treated group compared the ECM patch group (Figure 6B). Interestingly, we found a 
1.518-fold increase in expression level of matricellular protein periostin (POSTN) and 1.663-fold 
overexpression of tissue transglutaminase-2 enzyme (TGM2) with AAMs transplantation (Figure 7 
and Data File S1). These protein-level changes provide molecular-level insight into the AAMs’ 
therapeutic mechanism of action. 
Septal zone—Similar to the subtransplant area, Actin cytoskeleton signaling and RhoA 
signaling pathways were predicted to be activated by the AAMs. Glutathione redox reactions I, 
with increased expression levels of GPX3 and GSTM2 enzymes, were also significantly altered 
(Figure 6A, Data File S1). In the AAMs patch group, functions related to a dominant prosurvival 
effect in remote septum were increased. At the cellular level, Cell viability was predicted to be 
activated (z-score +2.546), while Cell death and Apoptosis were decreased (z-scores -2.241 and -
2.685, respectively, Figure 6B). At the system level, the functions Morbidity or mortality and 
Organismal death were predicted to be decreased (z-scores -2.481 and -2.793, respectively, Figure 
6B). Notably, overexpression of both matricellular protein POSTN (1.852-fold) and TGM2 enzyme 
(1.996-fold) were also detected here following AAMs transplantation suggesting a wide-spread 
therapeutic effect (Figure 7). 
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All associated canonical pathways as well as biological functions and disease states are 
presented in Figures S3 and S4. Supplemental Table S2 further presents all associated DEPs to 
each canonical pathway, biological function and disease state.  
 
Immunohistochemistry and qRT-PCR 
To qualitatively assess the expression of selected DEPs identified, we performed 
immunohistochemical staining for POSTN, TGM2 and GPX1 (see Figure 8A). POSTN expression 
localized specifically to the extracellular space of the scar-myocardium interphase mostly in the 
subtransplant area. This kind of spatial staining pattern is well in line with the earlier reports on 
POSTN expression in the heart after acute MI.
16
 On the other hand, TGM2 expression mainly 
localized to the patch and intracellular compartment of the cardiomyocytes near the minor scar 
areas while GPX1 expression demonstrated less pronounced staining but localized in the 
myocardium to the cardiomyocytes near the scar areas and vascular walls and more intense in the 
patch areas. Results from quantitative real-time PCR (qRT-PCR) confirmed overexpression, in 
both subtransplant and septal zones, for Postn, Myh7 and Gpx3 (Figure 8B). The mRNA expression 
levels for Postn, Myh7 and Gpx3 were significantly higher only in AAMs patch group when 
compared to the Sham (P=0.010, P=0.014 and P=0.028 respectively). Moreover, the expression of 
Gpx3 was higher in AAMs patch compared to ECM patch group (P=0.046). Tgm2 mRNA levels 
did not show significant changes between groups. When comparing the gene and protein 
expression results, it is important to consider the substantial differences and variation in biological 
regulation and temporal dynamics between transcription and translation.
17
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Discussion 
In a murine model of MI and HF, epicardial patch therapy demonstrated significantly 
improved cardiac function, greatly preserved myocardial structure, attenuated ventricular wall 
scarring, and dramatically restricted tissue damage. Myocardial site-targeted proteomics revealed 
the selective cell and molecular-level therapeutic effects of AAMs. These included activation of 
cardiomyogenesis, angiogenesis and anti-inflammation pathways, as well as reduction of oxidative 
stress. 
Cell-based therapies have long been investigated for their ability to deliver regenerative 
effects. Atrial appendages act as niches for cardiac progenitor cells and serve as a rational 
autologous source of myocardial tissue for therapy due to their easy accessibility and relative 
redundancy for cardiac function.
11,12
 We mechanically disaggregate the atrial appendage tissue after 
harvesting to yield micrografts ready for epicardial transplantation.
18
 
Here, we utilized mass-spectrometry-based quantitative proteomics to decipher myocardial 
site-specific responses to epicardial AAMs after MI. We demonstrate a widespread 
cardioprotective effect reaching from the subtransplant myocardium to remote myocardial areas. In 
the subtransplant area, decreased oxidative metabolism and oxidative stress with increased 
glutathione metabolism suggest an AAMs-induced change in metabolism towards glycolysis, a 
process associated with improved regeneration capacity in multiple studies.
19-23
 We propose that 
AAMs induced, likely through a paracrine mechanism, a metabolic shift from oxidative to 
glycolytic metabolism in the ischemically challenged subtransplant area and a pro-reparative 
microenvironment for surviving cardiomyocytes, ultimately setting the stage for functional 
recovery. This effect is further supported by our observation that functions such as “Formation of 
muscle” and “Differentiation of muscle cells” were activated. Moreover, restoration of functional 
myocardial tissue is not merely a process of cardiomyocytes, but necessitates formation of new 
ECM, blood vessels, and lymphatics, all processes of which are mostly orchestrated by cell types 
other than cardiomyocytes. Our findings demonstrate increased angiogenesis, vasculogenesis, and 
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widespread prosurvival changes in the myocardium, which indicate induction of a protective and 
restorative myocardial environment by AAMs.  
Increased expression of the cardiomyocyte mitogen and matricellular protein POSTN in 
both the subtransplant and remote septal zones, further clarifies the cellular and molecular 
mechanisms of AAMs patch transplantation. The secreted matricellular protein POSTN mediates 
cell-matrix interactions and repair after tissue injury.
24,25
 Our data support the association of 
POSTN expression and myocardial regenerative signaling via the Rho-kinase pathway.
16
 During 
tissue repair and healing after myocardial infarction, POSTN is secreted to the cardiac interstitium 
by activated cardiac fibroblasts
16
 POSTN to stimulate cardiomyocyte cell cycle re-entry and 
prevent myocardial rupture after infarction.
16,24
 
In the subtransplant myocardium, AAMs selectively increased expression of proteins 
associated with muscle formation, vasculature development, and glutathione metabolism. DEPs 
were also negatively associated with cellular infiltration. In both subtransplant and septal 
myocardium, remote to the transplant site, we discovered increased expression of proteins 
associated with cardiomyocyte contraction (including MYH7, MYL1, MYL6, MYL12B, ACTA1, 
ACTN4, DES and CAMK2D). Interestingly, the expression of proteins involved in glutathione 
metabolism and antioxidant defenses (GSTM2, GSTA4, GPX3) were also significantly increased 
in the subtransplant and remote septal sites treated by AAMs patch therapy compared with those 
treated by ECM patch therapy without micrografts. The observed Gpx3 gene expression difference 
between AAMs and ECM patch groups further strengthens this association of the AAMs 
mechanism of action via enhanced myocardial antioxidant defenses. In addition, we found a 
significant increase in cell viability and a significant decrease in cell death and apoptosis in the 
septal zone in AAMs patch-treated hearts. This prosurvival action is a documented paracrine effect 
of cardiac stem/progenitor cell therapy.
26
 
Interestingly, the AAMs treatment suppressed inflammatory reactions in the ischemia-
challenged subtransplant zone and increased angiogenesis. Proteins associated with muscle cell 
differentiation were also upregulated in this zone treated with AAMs. Thus, our results suggest that 
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AAMs can modulate the inflammatory response following MI in a way that promotes functional 
myocardial recovery. 
While the AAMs selectively induce therapeutic myocardial signaling and protein 
expression after MI, our results indicate that the ECM patch itself also protects against 
experimental MI and fibrosis. As a mechanically supportive structure, the epicardial ECM patch 
can alter the biomechanics of the failing left ventricle in a beneficial manner. By increasing wall 
thickness, ECM patch transplantation can relieve tension in the myocardial wall and subsequently 
reduce oxygen demand. An epicardial ECM patch may also modify the mechanical force vectors 
along the ventricular wall to favor an energetically more beneficial contraction. 
Although our study provided indirect insights into AAMs survival on the epicardial surface 
after MI, a targeted evaluation of the extent of autologous graft survival utilizing AAMs-specific 
experimental long-term labeling methodologies would be required to unequivocally address the 
extent and duration of a graft survival. Interestingly, however, we found an abundant tissue nodules 
staining, negative for collagen using Picrosirius Red. The higher expression of ANP mRNA that 
was observed in AAMs patch group's transplant zone and apices relative to same areas in the ECM 
patch group, can also indicate persistence of the AAMs. 
This study complements our previously reported first clinical application of autologous 
AAMs patch epicardial transplantation,
14 
and the clinical open label safety and feasibility trial 
(ClinicalTrials.gov identifier NCT02672163).
15
 Our results here provide insights into the 
mechanisms of action of epicardial AAMs patch transplantation, and associate its therapeutic 
effects, reduced cardiac fibrosis and preservation of functional myocardium, with activation of 
pathways responsible for angio- and cardiogenesis in the ischemically damaged myocardium. 
Contrary to the long-lasting trend of developing cardiac cellular therapies with increasing 
complexity, our results underscore the therapeutic possibilities of readily clinically applicable and 
straight-forward autologous procedures. 
In conclusion, the therapeutic effect of the AAMs patch is mediated through multifaceted 
synergy between 1) mechanical support with ventricular unloading by the ECM patch 
transplantation, as demonstrated by improved ECHO parameters, attenuated fibrosis and 
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preservation of troponin T-positive myocardium in both acellular ECM as well as in AAMs patch-
treated groups; 2) enhanced cardiomyocyte contractility through expression of proteins associated 
with contractile apparatus and Ca2+ signaling in the AAMs patch group; 3) enhanced reparative 
microenvironment through activated anaerobic glycolysis, angiogenesis and cell viability; 4) 
decreased oxidative stress and enhanced antioxidant protection by increased glutathione 
metabolism; 5) upregulated CM mitogenic matricellular POSTN; and 6) modulated inflammation. 
These results provide a molecular basis for epicardial AAMs patch transplantation therapy in 
ischemic heart failure for myocardial rescue and repair. 
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Methods 
A full-length description of the methods is available as an online-only data supplement 
(Detailed Materials and Methods). Figure 1 summarizes the study protocol. A brief overview of the 
methods is presented here. 
Both atrial appendages were harvested and processed to AAMs from three male donor 
mice for each syngeneic transplant (42 mice in total). Forty age-matched male mice (inbred 
129X1/SvJ mice, JAX stock #000691, The Jackson Laboratory, Bar Harbor, ME, USA) were 
divided into the following groups: Sham-operated (Sham group, n=4); left anterior descending 
artery (LAD) ligation to induce MI (MI group, n=9); LAD ligation followed by epicardial 
transplantation of ECM patch without AAMs (ECM patch group, n=13); and LAD ligation 
followed by AAMs patch, an ECM patch with AAMs, transplantation (AAMs patch group, n=14). 
Cardiac function was evaluated weekly by ECHO, and after an 8-week follow-up, animals were 
sacrificed and hearts collected for analyses, including: (1) ANP expression with qRT-PCR from 
heart apices, (2) ventricular morphometric assessment with wall thickness, scar transmurality and 
planimetric measurements, (4) histological evaluation for myocardial preservation with antibody 
and PicroSirius Red stain against cTnT and collagens, respectively. Collagen staining was further 
supplemented with microscopy using circularly polarized light to subtype mature (type I) and 
immature (type III) collagens.  
Another set of mice was used to evaluate the mechanisms of AAMs. Male mice (strain 
129X1/SvJ) were divided into three groups to receive either epicardial ECM (n=7) or AAMs (n=7) 
patch therapy after MI or Sham control (n=4). As previously described, animals were sacrificed, 
hearts were collected, but here cryopreserved after the 8-week follow-up. Transplant, subtransplant 
and remote septal tissue samples were dissected from thin cryosections and subsequently processed 
for label-free site-targeted proteomic analysis (DIA-nanoLC-HD-MS
E
; AAMs patch, n=4x3; ECM 
patch, n=4x3). Prior to bioinformatic analyses using IPA® software, the proteomic data were 
scrutinized by Principal Component Analysis, resulting in the exclusion of outliers, and by 
Spearman correlation heatmap. The results were validated using antibody staining on tissues 
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(targeting POSTN, TGM2 and GPX1 proteins) and by qRT-PCR, assaying Postn, Tgm2, Gpx3 and 
Myh7 mRNA transcripts. The proteomics data have been deposited to the Mass Spectrometry 
Interactive Virtual Environment (MassIVE; dataset MSV000084120). 
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Figure 1. Overview of the study protocol.
A schematic presentation of the processes carried out in the operating room and subsequently in the laboratory are 
illustrated. For further information, see the Detailed Materials and Methods. 1. For each AAMs patch, both left and right 
atrial appendages were harvested from three syngeneic donor mice after placement of an atrial clip. 2. and 3. Harvested 
appendages were disaggregated to atrial appendage micrografts (AAMs) with a Rigenera machine. 4. An ECM sheet 
(CorMatrix® ECM™ for cardiac tissue repair) was peeled into four layers, and 1-ply sheets were cut into circles using an 8 
mm diameter tissue punch. To create an AAMs patch, we evenly dispersed the AAMs suspension, containing tissue 
material from six appendages (three from both the right and left sides), onto the matrix sheet and sealed with a thin layer 
(10 l volume) of fibrin tissue glue. 5. The AAMs patch was subsequently fitted onto the recipient heart with the AAMs-
containing side facing the epicardium of the left ventricle at the site of infarction. The transplant was further fixed to the 
myocardium by three sutures to ensure that the patches remained in place. 6. After the 8-week follow-up, animals were 
sacrificed, hearts were excised, and ventricular tissue samples were collected for histology or snap frozen in liquid 
nitrogen. Apices were also collected for the measurement of ANP mRNA expression with qRT-PCR. 7. Thin histological 
sections were used for immunohistochemistry and morphometry. 8. and 9. Cryosections of 12-µm thickness were 
collected from three anatomic groups (transplant/patch, subtransplant and septum) for proteomic profiling. 10. Lastly, 
rest of the cryopreserved samples were used for selected validative qRT-PCR measurements, and paraffin embedded 
tissue samples for IHC-P staining.
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Figure 2. Myocardial function.
A, left panel shows weekly performed LVEF measurements; right panel shows AUC analysis from the LVEF follow-up data. B, left panel 
shows the circumferential strain measured with ECHO at 2-week intervals; the right panel shows the corresponding AUC. C, AUC analysis 
of the circumferential strain rate. D, AUC analysis of the longitudinal strain; E, AUC analysis of the longitudinal strain rate. F, relative 
expression of ANP mRNA to expression of 18S mRNA from apex tissue samples as analyzed by real-time PCR. */†/‡, p-value <0.05; **/††/
‡‡, p-value <0.01; ***/†††/‡‡‡, p-value <0.001; *, p-value vs. the ECM patch group; †, p-value vs. the MI group; ‡, p-value vs. the Sham 
group. Two-tailed Mann-Whitney t-test was applied and data normality assessed with Shapiro-Wilk test for normality. The scatter plot data 
represent mean ± SEM. The n-values represent separate mice measured with high confidence and in regard to ANP expression, number of 
analyzed heart apices. 
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Figure 3. Ventricular morphometry.
A, infarction scar transmurality assessed by measuring the thickness of collagen-containing tissue and comparing it to the 
total thickness of the ventricular wall. B, ventricular wall thickness; thickness of the transplant was included in the 
measurement. C, planimetry analysis of the infarction scar angle. D, representative sections of Picrosirius Red-stained tissue 
samples assessed for tissue morphometry and infarction scar transmurality. Scale bars equal 2mm. */†/‡, p-value <0.05; **/ 
††/‡‡, p-value <0.01; ***/†††/‡‡‡, p-value <0.001; *, p-value vs. the ECM patch group; †, p-value vs. the MI group; ‡, p-value 
vs. the Sham group. Two-tailed Mann-Whitney t-test was applied and data normality assessed with Shapiro-Wilk test for 
normality. From each heart sample, three adjacent histological sections were cut for analysis. The n-values represent total 
measurement sites assessed with high confidence (A and B, 9 measurements/sample; C 3 measurements/ sample).
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Figure 4. Evaluation of fibrosis.
A, illustration of collagen analysis. Upper pictures are representative illustrations of the 
cardiac tissue sections photographed with circularly polarized light. Lower magnified and 
representative images were obtained from the endocardial surface of the infarction area from 
the left ventricle using 40 x magnification. The scale bar equals 1mm. B, Quantitational 
analysis of collagen fiber subpopulations from the endocardium. The uppermost panel shows 
the total content of Picrosirius Red-positive fibers in the tissue samples analysed, while the 
panels below present the amount of the birefringent, orange and green fibers seen with 
circularly polarized light, respectively below. Using Picrosirius Red staining and circularly 
polarized light, thinner type-III fibers appear green, whereas thicker and more mature type-I 
fibers appear red or yellow.*/†/‡, p-value <0.05; **/††/‡‡, p-value <0.01; ***/†††/‡‡‡, p-value 
<0.001; *, p-value vs. the ECM patch group; †, p-value vs. the MI group; ‡, p-value vs. the 
Sham group. Two-tailed Mann-Whitney t-test was applied and data normality assessed with 
Shapiro-Wilk test for normality. The scatter plot data represent mean ± SEM. The n-values 
represent pooled sample means measured with high confidence. Each mean consists of 7 
endocardial measurements and represents a separate heart sample.
         
AAM patch
AAM patch ECM patch
N
A
AAM patch ECM patch MI
Ar
ea
 o
f t
iss
ue
 n
od
ule
s
gative particles Area of PicroSirius 
Red negative tissue
ECM patch MI Sham
Ar
ea
 o
f t
iss
ue
 n
od
ule
s i
n
pix
els
AAM patch
ECM patch
MI
Sham
A B
C D
E
Figure 5. Histological preservation of myocardium.
A, Quantitation of Troponin T positive tissue content in the adjacent myocardium to the 
transplant, the subtransplant zone. B, Similarly, quantitation of anti-troponin-T positively 
stained area in the transplant. C, number of nonfibrous tissue nodules larger than 100 
pixels inside the infarction scar (or the transplant area in AAM and ECM patch groups) in 
the Picrosirius Red-stained samples. D, area of the nonfibrous, Picrosirius Red negative 
tissue nodules. MI group values are presented as a reference. Reference values from 
the viable ventricular wall tissue (Sham) and from the infarction scar (MI) are also 
presented in the graph. E, selected representative sections from the 
immunohistochemical staining set with anti-troponin T antibody. The scale bar equals 
2mm. */†/‡, p-value <0.05; **/††/‡‡, p-value <0.01; ***/††† ‡‡‡, p-value <0.001; *, p-
value vs. the ECM patch group; †, p-value vs. the MI group; ‡, p-value vs. the Sham 
group. Two-tailed Mann-Whitney t-test was applied and data normality assessed with 
Shapiro-Wilk test for normality. Scatter plot data represent mean ± SEM. The n-values 
represent pooled sample means measured with high confidence. Each mean consists of 
multiple measurements and represents a separate heart sample.
         
Figure 6. Proteomics, canonical pathways and biological functions.
From each anatomical site, selected canonical pathways (A) and functions (B) are shown. The results are based on IPA® 
software analysis of given representative locational DEPs (shown in Data File S1). The Q-value represents the B-H p-value 
(Benjamini-Hochberg corrected p-value). Q-value ≥ 1.5 and |z-score| ≥ 2 were used as criteria for significant activation or 
inactivation of a given pathway or process. All detected changes were compared to the ECM patch group, thus, these 
changes were attributed to AAMs transplantation. At the end of each bar in the subplot (A) is the number of DEPs associated 
with a given pathway while in (B) the approximate z-score values are presented. Functions annotated with double asterisk 
(**) are shown further in Figure 7. All canonical pathways as well as diseases and functions identified in each anatomical site 
are provided in Figures S3 and S4, respectively.
         
Figure 7. DEPs and associated biological functions.
Selected biological functions from Figure 6 and associated DEPs are shown here. A, prosurvival functions and associated DEPs from the 
remote septum are presented. Periostin (POSTN) is documented cardiomyocyte mitogen and repair-mediator after ischemic cardiac damage. 
B, functions related to anabolic protein and muscle metabolism from the subtransplant are shown. Desmin (DES) is a pivotal intermediate 
filament in cardiomyocytes while Myosin 7 (MYH7) is a major slow twitch myosin isoform in the heart. C, DEPs associated with a decreased 
inflammatory reaction in the subtransplant are shown. Glutathione Peroxidase 1 (GPX1) is a ubiquitous enzyme with antioxidant properties 
catalysing the hydrolysis of hydrogen peroxide radical to water. D, DEPs associated with increased cardiomyocyte differentiation in the 
subtransplant immediately next to AAMs patch transplantation are shown. However, these functions showed only substantially strong trends 
towards activation and inactivation with a |z-score| = 1.9 for both functions (with criterion for significant activation or inactivation being |z-
score| ≥ 2.0). E, functions related to angiogenesis with associated DEPs in the subtransplant are shown. Transglutaminase 2 (TGM2) 
catalyses crosslinking of proteins and is associated in apoptosis, it is also documented to be prosurvival factor for cardiomyocytes following 
ischemic insult. Small numeric counts below each DEP represent the expression ratio in AAMs patch group divided by that of the ECM patch 
group. Statistical significance for differential protein expression was assessed using two-way ANOVA with p-value criterion ≤ 0.05.
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Figure 8. Validative IHC-P and qRT-PCR analyses.
The set of samples preserved in paraffin was used for evaluating the fibrotic content and overall histomorphology of the study groups by IHC-
P. Assessment by qRT-PCR was applied for the same set of cryopreserved samples as in the quantitative proteomics. A, The representative 
images with magnifying subcaptions from the IHC-P stainings are presented here for three selected proteins of interest: POSTN, TGM2 and 
GPX1 (n=4 for each). POSTN exhibited marked expression in the patch zone as well as in the extracellular interphase of fibrotic scar areas 
and myocardium in all groups. TGM2 expression was mainly localized to the intracellular compartment of cardiomyocytes and endothelial 
cells, with the most pronounced expression localizing to the cardiomyocytes with immediate contact to the fibrotic areas in the subtransplant 
zone right below the patch. Finally, the GPX1 exhibited marked expression in the patch itself and in the vascular wall. Intracellular expression 
in cardiomyocytes seemed to be more pronounced in AAMs group as compared to the ECM group. The black, green and blue scale bars 
equal 1000μm, 200μm and 100μm, respectively. B, The results of the qRT-PCR. Transcription of Myh7, Gpx3 and Postn, together with the 
production of the corresponding mRNAs, was significantly higher after AAMs patch transplantation (n=7) in comparison to the ECM patch 
transplantation (n=7), when both were compared against the steady state gene expression represented by the Sham expression levels (n=3). 
Tgm2 expression was not altered. */ ‡, p-value <0.05; **/‡‡, p-value <0.01; *, p-value vs. the ECM patch group; ‡, p-value vs. the Sham 
group. The p-values were calculated using one-way unpaired t-test with Welch’s correction for unequal variances. Normality of the data was 
assessed with Shapiro-Wilk normality test. The scatter plot data represents mean ± SEM. The n-values represent separate heart 
cryosamples measured with high confidence (1 cryosample/individual).
         
